Literature DB >> 30617773

Liver Resection for Hepatocellular Carcinoma in Non-alcoholic Fatty Liver Disease: a Multicenter Propensity Matching Analysis with HBV-HCC.

Tian Yang1, Lun-Yang Hu2,3, Zhen-Li Li2, Kai Liu2, Han Wu2, Hao Xing2, Wan Yee Lau2,4, Timothy M Pawlik5, Yong-Yi Zeng6, Ya-Hao Zhou7, Wei-Min Gu8, Hong Wang9, Ting-Hao Chen10, Jun Han2, Chao Li2, Ming-Da Wang2, Meng-Chao Wu2, Feng Shen11.   

Abstract

BACKGROUND: The incidence of hepatocellular carcinoma (HCC) in non-alcoholic fatty liver disease (NAFLD) is increasing worldwide. Higher perioperative risks may be anticipated due to underlying steatohepatitis, while long-term outcomes after liver resection are unknown. We sought to investigate outcomes after liver resection for NAFLD-HCC versus hepatitis B virus (HBV)-HCC using propensity score matching (PSM).
METHODS: Consecutive patients who underwent liver resection for HCC between 2003 and 2014 were identified from a multicenter database. Patients with NAFLD-HCC were matched one-to-one to patients with HBV-HCC.
RESULTS: Among 1483 patients identified, 96 (6.5%) had NAFLD-HCC and 1387 (93.5%) had HBV-HCC. Patients with NAFLD-HCC were older (median age 57 vs. 50 years), more often overweight (50.0% vs. 37.5%), less often to have cirrhosis (30.2% vs. 72.5%) and liver dysfunction (Child-Pugh B: 4.2% vs. 10.7%), had larger tumor size (median 7.2 vs. 6.2 cm) yet had better tumor differentiation (27.1% vs. 17.6%) compared with patients with HBV-HCC (all P < 0.05). Perioperative mortality and morbidity were comparable between the two groups (1.0% vs. 1.4% and 20.8% vs. 23.2%, both P > 0.05). No differences were noted in median OS and RFS among patient with NAFLD-HCC versus HBV-HCC before or after PSM.
CONCLUSION: While patients with NAFLD-HCC had different clinical characteristics than patients with HBV-HCC, liver resection resulted in similar perioperative outcomes and comparable OS and RFS among patients with NAFLD-HCC and HBV-HCC.

Entities:  

Keywords:  Hepatectomy; Hepatitis B virus; Hepatocellular carcinoma; Non-alcoholic fatty liver disease; Overall survival; Recurrence-free survival

Mesh:

Year:  2019        PMID: 30617773     DOI: 10.1007/s11605-018-04071-2

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  38 in total

1.  Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009.

Authors:  Zobair M Younossi; Munkhzul Otgonsuren; Linda Henry; Chapy Venkatesan; Alita Mishra; Madeline Erario; Sharon Hunt
Journal:  Hepatology       Date:  2015-10-24       Impact factor: 17.425

2.  Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030.

Authors:  Chris Estes; Quentin M Anstee; Maria Teresa Arias-Loste; Heike Bantel; Stefano Bellentani; Joan Caballeria; Massimo Colombo; Antonio Craxi; Javier Crespo; Christopher P Day; Yuichiro Eguchi; Andreas Geier; Loreta A Kondili; Daniela C Kroy; Jeffrey V Lazarus; Rohit Loomba; Michael P Manns; Giulio Marchesini; Atsushi Nakajima; Francesco Negro; Salvatore Petta; Vlad Ratziu; Manuel Romero-Gomez; Arun Sanyal; Jörn M Schattenberg; Frank Tacke; Junko Tanaka; Christian Trautwein; Lai Wei; Stefan Zeuzem; Homie Razavi
Journal:  J Hepatol       Date:  2018-06-08       Impact factor: 25.083

3.  Liver resection for hepatocellular carcinoma in patients with metabolic syndrome: A multicenter matched analysis with HCV-related HCC.

Authors:  Luca Viganò; Simone Conci; Matteo Cescon; Cristina Fava; Paola Capelli; Antonietta D'Errico; Guido Torzilli; Luca Di Tommaso; Felice Giuliante; Fabio Maria Vecchio; Mauro Salizzoni; Ezio David; Antonio Daniele Pinna; Alfredo Guglielmi; Lorenzo Capussotti
Journal:  J Hepatol       Date:  2015-01-31       Impact factor: 25.083

Review 4.  From NAFLD to NASH and HCC: pathogenetic mechanisms and therapeutic insights.

Authors:  Samuele De Minicis; Chris Day; Gianluca Svegliati-Baroni
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

5.  The natural history of nonalcoholic fatty liver disease: a population-based cohort study.

Authors:  Leon A Adams; James F Lymp; Jenny St Sauver; Schuyler O Sanderson; Keith D Lindor; Ariel Feldstein; Paul Angulo
Journal:  Gastroenterology       Date:  2005-07       Impact factor: 22.682

Review 6.  Should we undertake surveillance for HCC in patients with NAFLD?

Authors:  Ramy Younes; Elisabetta Bugianesi
Journal:  J Hepatol       Date:  2017-11-06       Impact factor: 25.083

Review 7.  EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma.

Authors: 
Journal:  J Hepatol       Date:  2018-04-05       Impact factor: 25.083

8.  Global trends and predictions in hepatocellular carcinoma mortality.

Authors:  Paola Bertuccio; Federica Turati; Greta Carioli; Teresa Rodriguez; Carlo La Vecchia; Matteo Malvezzi; Eva Negri
Journal:  J Hepatol       Date:  2017-03-21       Impact factor: 25.083

Review 9.  Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention.

Authors:  Zobair Younossi; Quentin M Anstee; Milena Marietti; Timothy Hardy; Linda Henry; Mohammed Eslam; Jacob George; Elisabetta Bugianesi
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-09-20       Impact factor: 46.802

10.  Temporal trends, clinical patterns and outcomes of NAFLD-related HCC in patients undergoing liver resection over a 20-year period.

Authors:  R Pais; L Fartoux; C Goumard; O Scatton; D Wendum; O Rosmorduc; V Ratziu
Journal:  Aliment Pharmacol Ther       Date:  2017-08-31       Impact factor: 8.171

View more
  7 in total

1.  Comparison of Safety and Efficacy of Yttrium-90 Radioembolization for Nonalcoholic Fatty Liver Disease-Associated and Hepatitis B Virus-Associated Hepatocellular Carcinoma.

Authors:  Lei Liang; Li-Yang Sun; Yong-Kang Diao; Tian Yang
Journal:  Liver Cancer       Date:  2020-03-10       Impact factor: 11.740

Review 2.  Hepatocellular carcinoma in non-alcoholic fatty liver disease-a review of an emerging challenge facing clinicians.

Authors:  Daniel Geh; Derek M Manas; Helen L Reeves
Journal:  Hepatobiliary Surg Nutr       Date:  2021-01       Impact factor: 8.265

3.  Long-term oncological prognosis after curative-intent liver resection for hepatocellular carcinoma in the young versus the elderly: multicentre propensity score-matching study.

Authors:  Jia-Le Pu; Zhong Chen; Lan-Qing Yao; Ji-Ye Feng; Yong-Kang Diao; Ming-Cheng Guan; Ju-Dong Li; Zheng-Liang Chen; Ya-Hao Zhou; Hong Wang; Wei-Min Gu; Jie Li; Chao Li; Ming-Da Wang; Hong Zhu; Ying-Jian Liang; Feng Shen; Timothy M Pawlik; Wan Yee Lau; Tian Yang
Journal:  BJS Open       Date:  2022-01-06

4.  Outcomes of Liver Resection for Metabolic Dysfunction-Associated Fatty Liver Disease or Chronic Hepatitis B-Related HCC.

Authors:  Lei Liu; Si Xie; Yu-Xian Teng; Zhu-Jian Deng; Kang Chen; Hao-Tian Liu; Rong-Rui Huo; Xiu-Mei Liang; Ping-Ping Guo; Da-Long Yang; Liang Ma; Bang-De Xiang; Le-Qun Li; Jian-Hong Zhong
Journal:  Front Oncol       Date:  2022-01-20       Impact factor: 6.244

Review 5.  Current Status of Research on the Role of Circular RNAs in Hepatocellular Carcinoma and Clinical Implications.

Authors:  Ren-Chao Zou; Ling-Lin Li; Hong-Ling Yuan
Journal:  Med Sci Monit       Date:  2020-08-11

Review 6.  Mechanisms of nonalcoholic fatty liver disease and implications for surgery.

Authors:  Ariel E Feldstein; Daniel Hartmann; Benedikt Kaufmann; Agustina Reca; Baocai Wang; Helmut Friess
Journal:  Langenbecks Arch Surg       Date:  2020-08-24       Impact factor: 3.445

7.  Is metabolic syndrome a risk factor in hepatectomy? A meta-analysis with subgroup analysis for histologically confirmed hepatic manifestations.

Authors:  Anastasia Murtha-Lemekhova; Juri Fuchs; Svenja Feiler; Erik Schulz; Miriam Teroerde; Eva Kalkum; Rosa Klotz; Adrian Billeter; Pascal Probst; Katrin Hoffmann
Journal:  BMC Med       Date:  2022-01-28       Impact factor: 8.775

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.